


Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. **(Original)** An imidazotriazinone compound represented by the following formula (IA) or (IB):



wherein

A is N or CR⁴;

B is N or CH;

R¹ is substituted or unsubstituted cycloalkyl group or tert-butyl group;

R² is a hydrogen atom or C₁-C₆ alkyl group;

R³ is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted C₂-C₆ alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: -NR⁵R⁶, -C(O)R⁷, -SO₂R⁷, -OR⁸, -NR⁸COR⁷, -NR⁸SO₂R⁷;

R⁴ is a hydrogen atom or C₁-C₃ alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R⁵ and R⁶ are, same or different from each other, a hydrogen atom; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted acyl group; or substituted or unsubstituted heterocycloalkyl group;

R⁷ is a hydrogen atom; substituted or unsubstituted C₁-C₆ alkyl group; substituted or unsubstituted heterocycloalkyl group; OH; -OR⁸ or -NR⁵R⁶;

R⁸ is a hydrogen atom, substituted or unsubstituted C₁-C₆ alkyl group; or substituted or unsubstituted heterocycloalkyl group; or pharmaceutically acceptable salts or solvates thereof.

2. **(Original)** The compound represented by the formula (IA) according to claim 1.

3. **(Withdrawn)** The compound represented by the formula (IB) according to claim 1.
4. **(Original)** The compound according to claim 1, in which R¹ is substituted or unsubstituted C₃-C₈ cycloalkyl group.
5. **(Previously Presented)** The compound according to claim 4, in which R¹ is cyclopentyl, cyclohexyl or cycloheptyl .
6. **(Previously Presented)** The compound according to claim 1, in which A is CR⁴ wherein R⁴ is methoxy or ethoxy group.
7. **(Previously Presented)** The compound according to claim 1, in which B is CH.
8. **(Previously Presented)** The compound according to claim 1, in which R² is methyl group.
9. **(Previously Presented)** The compound according to claim 1, in which R³ is a hydrogen atom; a halogen atom; saturated or unsaturated heterocycloalkyl group; an -NR⁵R⁶, -C(O)R⁷, or -SO₂R⁷ group, wherein R⁷ is OH, -OR⁸, -NR⁵R⁶ or a substituted or unsubstituted heterocycloalkyl group.
10. **(Previously Presented)** A pharmaceutical composition comprising a compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof as active ingredient.
11. **(Previously Presented)** A PDE 7 inhibitor comprising a compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof as active ingredient.